1. The immune response of hepatocellular carcinoma after locoregional and systemic therapies: The available combination option for immunotherapy
   Yuxin Duan et al, 2023, BioScience Trends CrossRef
2. Apoptosis induction and ERK/NF‐κB inactivation are associated with magnolol‐inhibited tumor progression in hepatocellular carcinoma in vivo
   Jai‐Jen Tsai et al, 2020, Environmental Toxicology CrossRef
3. Synthesis and biological evaluation of novel benzylidene-succinimide derivatives as noncytotoxic antiangiogenic inhibitors with anticolorectal cancer activity in vivo
   Kaixiu Luo et al, 2019, European Journal of Medicinal Chemistry CrossRef
4. Beneficial effect of fluoxetine on anti-tumor progression on hepatocellular carcinoma and non-small cell lung cancer bearing animal model
   Li-Cho Hsu et al, 2020, Biomedicine & Pharmacotherapy CrossRef
5. Cryptotanshinone inhibits the growth and invasion of colon cancer by suppressing inflammation and tumor angiogenesis through modulating MMP/TIMP system, PI3K/Akt/mTOR signaling and HIF-1α nuclear translocation
   Lin Zhang et al, 2018, International Immunopharmacology CrossRef
6. The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma
   Cheng-Chan Yu et al, 2020, Molecules CrossRef
7. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage
   Meghna Mehta et al, 2021, International Journal of Radiation Biology CrossRef
8. Fluoxetine Induces Apoptosis through Extrinsic/Intrinsic Pathways and Inhibits ERK/NF-κB-Modulated Anti-Apoptotic and Invasive Potential in Hepatocellular Carcinoma Cells In Vitro
   Wei-Ting Chen et al, 2019, International Journal of Molecular Sciences CrossRef
9. Advances in the Anti-Tumor Activity of Biflavonoids in Selaginella
   Mengdie Ren et al, 2023, International Journal of Molecular Sciences CrossRef
10. Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo
    Mao-Chi Weng et al, 2019, Biomedicine & Pharmacotherapy CrossRef
11. QNZ exposure induces development toxicity and mechanisms of hatching inhibition in large-scale loach (Paramisgurnus dabryanus) embryos
    Xiaohua Xia et al, 2023, Ecotoxicology and Environmental Safety CrossRef
12. Regorafenib Regulates AD Pathology, Neuroinflammation, and Dendritic Spinogenesis in Cells and a Mouse Model of AD
    Kyung-Min Han et al, 2020, Cells CrossRef
13. New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis
    Xin Li et al, 2023, Biomedicine & Pharmacotherapy CrossRef
14. Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma
    I.-Tsang Chiang et al, 2022, Neurotherapeutics CrossRef
15. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families
    Xiao-xiao He et al, 2018, Biochemical and Biophysical Research Communications CrossRef
16. Multifaceted role of NF-κB in hepatocellular carcinoma therapy: Molecular landscape, therapeutic compounds and nanomaterial approaches
    Reena Gupta et al, 2023, Environmental Research CrossRef
17. Advances in pharmacotherapeutics for hepatocellular carcinoma
    Lucia Cerrito et al, 2021, Expert Opinion on Pharmacotherapy CrossRef
18. Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances
    Blanca Cucarull et al, 2022, Cancers CrossRef
19. Regorafenib: a promising treatment for hepatocellular carcinoma
    Lucia Cerrito et al, 2018, Expert Opinion on Pharmacotherapy CrossRef
20. Sirt3 promotes hepatocellular carcinoma cells sensitivity to regorafenib through the acceleration of mitochondrial dysfunction
    Ruobing Wang et al, 2020, Archives of Biochemistry and Biophysics CrossRef
21. Insights Into Amentoflavone: A Natural Multifunctional Biflavonoid
    Xifeng Xiong et al, 2021, Frontiers in Pharmacology CrossRef
22. Regorafenib enhances antitumor immune efficacy of anti-PD-L1 immunotherapy on oral squamous cell carcinoma
    I-Tsang Chiang et al, 2022, Biomedicine & Pharmacotherapy CrossRef
23. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers
    Flavia Fondevila et al, 2019, Experimental & Molecular Medicine CrossRef
24. Induction of apoptosis through extrinsic/intrinsic pathways and suppression of ERK/NF‐κB signalling participate in anti‐glioblastoma of imipramine
    Fei-Ting Hsu et al, 2020, Journal of Cellular and Molecular Medicine CrossRef
25. Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice
    Mao-Chi Weng et al, 2018, Bioscience Reports CrossRef